APA (7th ed.) Citation

JR, H., YS, P., J, T., MA, L., S, L., AC, V., . . . A, S. (2025). Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): A randomised, open-label, phase 3 trial. Lancet (London, England), 406(10517), 2360. https://doi.org/10.1016/S0140-6736(25)02025-2

Chicago Style (17th ed.) Citation

JR, Hecht, et al. "Zanzalintinib Plus Atezolizumab Versus Regorafenib in Refractory Colorectal Cancer (STELLAR-303): A Randomised, Open-label, Phase 3 Trial." Lancet (London, England) 406, no. 10517 (2025): 2360. https://doi.org/10.1016/S0140-6736(25)02025-2.

MLA (9th ed.) Citation

JR, Hecht, et al. "Zanzalintinib Plus Atezolizumab Versus Regorafenib in Refractory Colorectal Cancer (STELLAR-303): A Randomised, Open-label, Phase 3 Trial." Lancet (London, England), vol. 406, no. 10517, 2025, p. 2360, https://doi.org/10.1016/S0140-6736(25)02025-2.